Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study (Q87679931)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

title

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

phase III clinical trial

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Stephen Nicholls

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

5

Steven E Nissen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

10

John J P Kastelein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Barbara Sjouke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Gisle Langslet

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Maria Öhlander

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Paul W Ladenson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Anders G Olsson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

G Kees Hovingh

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

18 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

The Lancet: Diabetes & Endocrinology

14 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

455-463

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

14 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Prevalence and Correction of Hypothyroidism in a Large Cohort of Patients Referred for Dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ) agonists for the treatment of dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Effect of long-term administration of desiccated thyroid on serum lipoprotein and cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Update in Lipid Alterations in Subclinical Hypothyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Drug-Related Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Incidence of drug-induced hepatic injuries: a French population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Safety of statins: focus on clinical pharmacokinetics and drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970006-3

7 January 2021

10.1016/S2213-8587(14)70006-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24731671%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference